Bionano Genomics (NASDAQ:BNGO) Releases Earnings Results, Beats Estimates By $0.12 EPS

Bionano Genomics (NASDAQ:BNGO) issued its quarterly earnings results on Wednesday. The company reported ($0.76) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.12, reports. The company had revenue of $6.69 million for the quarter, compared to analyst estimates of $6.57 million. Bionano Genomics had a negative net margin of 109.94% and a negative return on equity of 67.90%.

Here are the key takeaways from Bionano Genomics’ conference call:

• Revenue came in at $6.7 million in Q1 2026, up 4% year over year and at the high end of guidance, while flow cell sales hit a record first-quarter level of 8,178 units.
• Consumable revenue rose 20% year over year to $3.9 million, reflecting stronger usage from existing customers and a shift toward more recurring revenue.
• The company highlighted major reimbursement wins for OGM, including a 47% increase in the payment determination for hematologic malignancies and a new category 1 CPT code for constitutional genetic disorders.
• Adjusted gross margin improved to 49% in Q1 from 46% a year ago, and management said the company expects its cash runway to extend into 2027.
• Management said Bionano does not expect to reach operating cash flow break-even by the end of 2026, though it aims to reduce burn further by Q4 2027.

Bionano Genomics Trading Down 2.1%

Shares of NASDAQ:BNGO traded down $0.03 during mid-day trading on Friday, hitting $1.17. The company had a trading volume of 130,173 shares, compared to its average volume of 283,922. The company has a market capitalization of $12.92 million, a PE ratio of -0.27 and a beta of 1.62. Bionano Genomics has a one year low of $1.06 and a one year high of $5.50. The firm has a fifty day moving average price of $1.20 and a 200 day moving average price of $1.39. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.98 and a quick ratio of 1.74.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on BNGO shares. HC Wainwright reduced their price target on Bionano Genomics from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Weiss Ratings upgraded Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a report on Friday, May 1st. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Bionano Genomics has an average rating of “Hold” and a consensus target price of $6.00.

Hedge Funds Weigh In On Bionano Genomics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. DRW Securities LLC bought a new stake in Bionano Genomics in the 4th quarter valued at about $258,000. Geode Capital Management LLC boosted its holdings in Bionano Genomics by 148.8% in the fourth quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock worth $102,000 after acquiring an additional 39,928 shares in the last quarter. Renaissance Technologies LLC bought a new position in shares of Bionano Genomics in the 4th quarter worth $57,000. Jane Street Group LLC acquired a new stake in Bionano Genomics in the 4th quarter valued at $34,000. Finally, Carret Asset Management LLC increased its stake in Bionano Genomics by 76.4% during the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after purchasing an additional 19,100 shares in the last quarter. Institutional investors own 11.35% of the company’s stock.

About Bionano Genomics

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high?resolution genome analysis tools designed to map structural variants and large?scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase?length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.